Entities / Company
10X Genomics.
American biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 84
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Analyst firm upgraded price objective on 10X Genomics stock.Some support1 report
-
Investment firms made various stake adjustments in 10X Genomics across Q2, Q3, and Q4 2026.Some support1 report
-
Financial firms (RBC, Citigroup, Morgan Stanley) issued rating and price target updates for 10X Genomics.Some support4 reports
-
Two healthcare technology companies, 10X Genomics and MaxCyte, Inc., are selling products across China, Africa, Europe, and the Middle East.Some support1 report
-
Lausanne University Hospital, 10X Genomics, and Cleveland Clinic announced a new research partnership focused on clinical diagnostics.Some support2 reports
-
10X Genomics and Takara Bio reported a 15% revenue increase across Europe, the Middle East, and Africa.Some support1 report
-
Settlement revenue tied to 10X Genomics' business involves Takara Bio.Some support1 report
-
10X Genomics and American Well Corporation are being compared as medical companies.Some support1 report
Gone quiet
No new reports in 90+ days-
10X Genomics filed its required 13F reports with the Securities and Exchange Commission and its stock continues to trade on the Nasdaq exchange.Well supported6 reports
-
Barclays boosted its price target for 10x Genomics, which also announced a new research collaboration.Some support2 reports
-
Share prices of Outset Medical and 10X Genomics are being benchmarked against the S&P 500 based on market factors.Some support1 report
-
A director of 10X Genomics sold shares of the company's stock.Some support3 reports
-
Patent litigation between Bruker and 10X Genomics was resolved via a global settlement requiring quarterly payments and royalties.Speculative1 report
-
The life sciences sector supports biotech and pharmaceutical R&D, with companies like 10X Genomics and UFP Technologies designing custom solutions for medical devices.Speculative1 report
-
10X Genomics used LinkedIn and complied with Regulation FD disclosure obligations.Some support1 report
-
10X Genomics underperformed the S&P 500 market so far this year.Some support1 report1 development inside
-
10X Genomics stock fell short of S&P 500's gain on July 29, 2025.Some support1 report
-
10X Genomics received a rating upgrade on August 7, 2025, due to positive earnings outlook.Some support1 report
-
10X Genomics partnered with the Genome Institute of Singapore regarding the TISHUMAP initiative on August 8, 2025.Some support2 reports
-
10X Genomics announced an acquisition of Scale Biosciences on August 8, 2025, which is expected to provide key inventions and technologies.Some support1 report
-
10X Genomics outperformed the S&P 500 by 10.9% on August 22, 2025.Some support2 reports
-
UnitedHealth Group and 10X Genomics were noted to operate in the health insurance sector.Some support1 report
-
Serge Saxonov was appointed CEO of 10X Genomics on August 14, 2025, while market figures questioned funding trends and acquisitions.Some support2 reports
-
10X Genomics announced enhancements to its Xenium platform, enabling simultaneous RNA and protein detection in the same cell, along with ready-to-use protein subpanels.Some support2 reports
-
10X Genomics participated in a conference hosted by Morgan Stanley on August 28, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around 10X Genomics this week
News at the entities that move 10X Genomics most-
Securities and Exchange Commission StructuralManufacturers Life Insurance Company increased its stake in a South Korea ETF and filed the disclosure with the SEC.Moves 10X Genomics
-
Morgan Stanley OperationalMorgan Stanley increased its price target for SLM Corporation on September 2, 2026.Moves 10X Genomics
-
Bank of America Mentioned togetherBank of America provided a rating report on Cencora, which is being tracked by MarketBeat.Moves 10X Genomics
-
Barclays Mentioned togetherVenkatakrishnan has been appointed to lead a group within Barclays.Moves 10X Genomics
-
Nasdaq StructuralEnvoy Medical Inc. is trading on the Nasdaq Capital Market, with Equiniti serving as its transfer agent.Moves 10X Genomics
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada adjusted its holdings in the Simplify Hedged Equity ETF on October 22, 2026.Moves 10X Genomics
Connections
The 18 strongest of 84, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Securities and Exchange Commission Structural
10X Genomics operates under formal regulatory oversight, complying with disclosure and reporting obligations set by the SEC.
-
Morgan Stanley Operational
Morgan Stanley provides financial analysis and ratings for 10X Genomics, and the company participates in MS market events.
-
Nasdaq Structural
10X Genomics is formally listed and trades on the Nasdaq stock exchange.
-
Bruker Structural
A and B resolved a patent dispute via a global settlement requiring ongoing royalties and quarterly payments.
-
Lausanne University Hospital Operational
Lausanne University Hospital and 10X Genomics have established a research partnership for clinical diagnostics.
-
Takara Bio Transactional
The relationship is defined by a current revenue stream derived from licenses and royalties tied to 10X Genomics' business operations.
-
Middle East Shared context
10X Genomics actively sells products and generates revenue within the Middle East market.
-
Cleveland Clinic Operational
The two entities are engaged in an active research partnership focused on clinical diagnostics.
Show all 18 connections
-
Barclays Mentioned together
Barclays provides market coverage, including price targets and Overweight ratings, for 10X Genomics.
-
Royal Bank of Canada Mentioned together
RBC analysts provided market coverage on 10X Genomics, culminating in an upgrade to a hold rating.
-
ARGUS Mentioned together
Market analysts initiated coverage on both companies with a Buy rating.
-
MarketBeat Mentioned together
MarketBeat publishes average ratings and consensus price targets for 10X Genomics.
-
Shehnaaz Suliman Transactional
Shehnaaz Suliman, in her capacity as a director, sold shares of 10X Genomics stock.
-
Africa Shared context
10X Genomics operates and generates revenue within the African market context.
-
Europe Shared context
10X Genomics operates within the European market, contributing to the region's reported revenue growth.
-
Bank of America Mentioned together
Bank of America provides stock analysis and price targets for 10X Genomics.
-
Leerink partners Mentioned together
A analyst firm provides coverage and price objective recommendations for B.
-
Citigroup Mentioned together
Citigroup provided a price objective and neutral rating for 10X Genomics.
History
Events by the month they beganSeptember 2026
3 eventsAugust 2026
4 events- Two healthcare technology companies, 10X Genomics and MaxCyte, Inc., are selling products across China, Africa, Europe, and the Middle East.
- Lausanne University Hospital, 10X Genomics, and Cleveland Clinic announced a new research partnership focused on clinical diagnostics.
- 10X Genomics and Takara Bio reported a 15% revenue increase across Europe, the Middle East, and Africa.
- Settlement revenue tied to 10X Genomics' business involves Takara Bio.
July 2026
1 eventShow 1 earlier month
June 2026
17 events- 10X Genomics filed its required 13F reports with the Securities and Exchange Commission and its stock continues to trade on the Nasdaq exchange.
- Barclays boosted its price target for 10x Genomics, which also announced a new research collaboration.
- Share prices of Outset Medical and 10X Genomics are being benchmarked against the S&P 500 based on market factors.
- A director of 10X Genomics sold shares of the company's stock.
- Patent litigation between Bruker and 10X Genomics was resolved via a global settlement requiring quarterly payments and royalties.
- The life sciences sector supports biotech and pharmaceutical R&D, with companies like 10X Genomics and UFP Technologies designing custom solutions for medical devices.
- 10X Genomics used LinkedIn and complied with Regulation FD disclosure obligations.
- 10X Genomics underperformed the S&P 500 market so far this year.
- 10X Genomics stock fell short of S&P 500's gain on July 29, 2025.
- 10X Genomics received a rating upgrade on August 7, 2025, due to positive earnings outlook.
- 10X Genomics partnered with the Genome Institute of Singapore regarding the TISHUMAP initiative on August 8, 2025.
- 10X Genomics announced an acquisition of Scale Biosciences on August 8, 2025, which is expected to provide key inventions and technologies.
- 10X Genomics outperformed the S&P 500 by 10.9% on August 22, 2025.
- UnitedHealth Group and 10X Genomics were noted to operate in the health insurance sector.
- Serge Saxonov was appointed CEO of 10X Genomics on August 14, 2025, while market figures questioned funding trends and acquisitions.
- 10X Genomics announced enhancements to its Xenium platform, enabling simultaneous RNA and protein detection in the same cell, along with ready-to-use protein subpanels.
- 10X Genomics participated in a conference hosted by Morgan Stanley on August 28, 2025.